Name: Latest research reports of Ajanta Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Expensive Performer

2576.8500 38.60 (1.52%)

NSE Mar 17, 2025 15:31 PM

26.06% Fall from 52W High

Volume: 93,024

Ajanta Pharma Ltd.

28 Oct 2024

2576.85

1.52%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered in-line performance in 2QFY25. Asia/Africa (47% of sales) grew strongly at 32% YoY in 2QFY25 due to superior execution and partly on the low base of the past year.

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.